Lipella Pharmaceuticals Inc.
LIPO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.07 | -0.17 | -0.00 |
| FCF Yield | -123.58% | -51.72% | -14.41% | -36.88% |
| EV / EBITDA | -0.21 | -0.64 | -3.10 | -0.83 |
| Quality | ||||
| ROIC | -258.28% | -144.65% | -50.73% | -110.30% |
| Gross Margin | -573.65% | -575.87% | -1,283.43% | -461.71% |
| Cash Conversion Ratio | 0.79 | 0.68 | 0.70 | 0.53 |
| Growth | ||||
| Revenue 3-Year CAGR | 42.81% | 20.13% | -42.36% | -28.00% |
| Free Cash Flow Growth | -24.84% | -72.82% | -85.10% | -3,361.77% |
| Safety | ||||
| Net Debt / EBITDA | 0.43 | 0.69 | 1.81 | 0.61 |
| Interest Coverage | 0.00 | -437.50 | -269.42 | -280.34 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 18.43 | 9.63 | 170.20 | -11.75 |